Dimerix Ltd
ASX:DXB

Watchlist Manager
Dimerix Ltd Logo
Dimerix Ltd
ASX:DXB
Watchlist
Price: 0.53 AUD 0.95%
Market Cap: AU$318.2m

Net Margin

-224.1%
Current
Improving
by 15 960.5%
vs 3-y average of -16 184.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-224.1%
=
Net Income
AU$-13.3m
/
Revenue
AU$5.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-224.1%
=
Net Income
AU$-13.3m
/
Revenue
AU$5.9m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Dimerix Ltd
ASX:DXB
314.2m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in Australia
Percentile
37th
Based on 4 004 companies
37th percentile
-224.1%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Dimerix Ltd
Glance View

Market Cap
318.2m AUD
Industry
Biotechnology

Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.

DXB Intrinsic Value
0.84 AUD
Undervaluation 37%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-224.1%
=
Net Income
AU$-13.3m
/
Revenue
AU$5.9m
What is Dimerix Ltd's current Net Margin?

The current Net Margin for Dimerix Ltd is -224.1%, which is above its 3-year median of -16 184.6%.

How has Net Margin changed over time?

Over the last 3 years, Dimerix Ltd’s Net Margin has increased from -437 108.3% to -224.1%. During this period, it reached a low of -437 108.3% on Jun 30, 2022 and a high of -224.1% on Jun 30, 2025.

Back to Top